Innovation is the lifeblood of
our company

We are committed to building a brighter future for patients. Using new
discoveries and insights in hematology, we are advancing the frontiers
of biology to create life-changing medicines.

A Focus on Hematology

Disc was founded with a single-minded focus on hematology. Blood is fundamental and runs through every aspect of life. But when blood is affected by disease, it can create suffering that is just as far reaching. From rare genetic disorders to blood cancers to complications of chronic diseases that affect millions, we saw areas of medicine with few options for patients, and to where we are dedicating ourselves to design and develop new therapies for these disorders.

Medicines that Matter

Our vision is to build a company that is geared toward bringing therapies that will matter to patients. In every aspect of our work, from the technology we pursue, to the talented team we have assembled, and to the partners we work with, our priority is taking promising new science and transforming it into something useful – medicines that we hope will heal, cure, and alleviate suffering.

John Quisel, JD, PhD
Chief Executive Officer
Jean Franchi
Chief Financial Officer
Jonathan Yu
Chief Operating Officer
Will Savage, MD, PhD
Chief Medical Officer
Pamela Stephenson, MPH
Chief Commercial Officer
Srikanth Venkatraman, PhD
SVP, Head of Chemistry
Hua Yang, PhD
SVP, Head of Early Development and Clinical Pharmacology
Sonia Razzetti, PhD
SVP, Quality
Rahul Khara, PharmD, JD
General Counsel
Min Wu, PhD
VP, Head of Innovation
Jeremy Brinkerhoff, CPA
VP, Finance
Jason Cathelyn, PhD
VP, Intellectual Property
Andeleeb Al Mobaraq-Dahy
VP, Regulatory Affairs
Katherine Watt Chan, PhD, MBA, MPH
VP, Portfolio and Program Management
Melanie Chin, PhD
VP, Clinical Development and Head of Medical Affairs
Donald Nicholson, PhD
Executive Chairman
Kevin Bitterman, PhD
Partner, Atlas Venture
John Quisel, JD, PhD
Chief Executive Officer
Liam Ratcliffe, MD, PhD
Head, Access Biotechnology
William White, MPP, JD
CFO, Akero Therapeutics
Mona Ashiya, PhD
Partner, Orbimed Advisors
Mark Chin, MS, MBA
Managing Director, Arix Bioscience
Georges Gemayel, PhD
Former Executive Chair, Gemini Therapeutics
Brian MacDonald, MB, ChB, PhD
Chair, Former CEO and CIO, Co-Founder of Disc Medicine
Mark Fleming, MD, DPhil
Pathologist-in-Chief, Department of Pathology, Professor of Pathology, Harvard Medical School
Tomas Ganz, MD, PhD
Distinguished Professor of Medicine and Pathology, David Geffen School of Medicine, UCLA
Elizabeta Nemeth, PhD
Professor of Medicine, David Geffen School of Medicine, UCLA
Stefano Rivella, PhD
Professor of Pediatrics and Chair of Pediatric Hematology Children’s Hospital of Philadelphia
Uma Sinha, PhD
CSO at BridgeBio Pharma, Former CSO at Global Blood Therapeutics
Srdan Verstovsek, MD, PhD
Professor of Medicine, Department of Leukemia, The University of Texas MD Anderson Cancer Center